A study of a GLP-1 and GIP medicine, tirzepatide, in people with endometrial cancer.
Recruiting now. Registry record last updated April 13, 2026.
- Who can join
- Adults 18+, women only, have endometrial cancer, BMI 25+.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Endometrial Cancer.
Full scientific study title: A Study of a Weight Loss Intervention in People With Endometrial Cancer.
Who can join
Adults 18+, women only, have endometrial cancer, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
- Obesity (defined as BMI ≥ 30 kg/m2) OR Overweight (defined as BMI ≥ 27 kg/m2) with presence of ≥1 weight related comorbid condition OR a diagnosis of Type 2 Diabetes Mellitus with BMI ≥ 25 kg/m2
- Type 2 Diabetes Mellitus is defined as known history of Type 2 diabetes, HbA1c ≥ 6.5%, fasting blood glucose ≥126 mg/dL on 2 occasions, or random blood glucose ≥ 200 mg/dL with signs and symptoms of diabetes mellitus (weight loss, fatigue, polyuria, polydipsia, vision changes)
- Patients with new diagnosis of stage I-III endometrial cancer
Key exclusion criteria
- Known Type 1 diabetes
- Known GAD, Islet Cell, or Zn Transporter 8 antibodies
- History of gastroparesis
- High risk for aspiration
- Active or history of chronic or acute pancreatitis
Where this trial is enrolling
This trial has 7 sites across 2 states. Contact a site coordinator directly to start screening.
New Jersey3 sites
- Memorial Sloan Kettering Basking RidgeBasking Ridge, New JerseySminu Bose, MD646-888-5427
- Memorial Sloan Kettering MonmouthMiddletown, New JerseySminu Bose, MD646-888-5427
- Memorial Sloan Kettering BergenMontvale, New JerseySminu Bose, MD646-888-5427
New York4 sites
- Memorial Sloan Kettering CommackCommack, New YorkSminu Bose, MD646-888-5427
- Memorial Sloan Kettering WestchesterHarrison, New YorkSminu Bose, MD646-888-5427
- Memorial Sloan Kettering Cancer CenterNew York, New YorkSminu Bose, MD646-888-5427
- Memorial Sloan Kettering NassauUniondale, New YorkSminu Bose, MD646-888-5427
Timeline
Started enrolling: December 19, 2024. Expected completion: December 2027. Last updated on ClinicalTrials.gov: April 13, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
